Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Aveanna $458.8 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Privia Health $525.8 million IPO
We advised Privia Health on its IPO and Nasdaq listing
Roivant Sciences combination with Montes Archimedes Acquisition
We are advising Roivant Sciences on its combination with a SPAC
EDAP TMS $28 million follow-on offering
We advised the underwriters on the equity offering
Zai Lab $857.5 million offering of American depositary shares and ordinary shares
We advised Zai Lab on the concurrent offerings
NeuroPace $102 million IPO
We advised the underwriters in connection with the IPO and Nasdaq listing
Lannett Company $350 million senior secured notes offering
We advised the initial purchasers on the high-yield notes offering
Akoya Biosciences $151.3 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Recursion Pharmaceuticals $500 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Diagnósticos da América R$3.3 billion equity offering
We advised the global coordinators and joint bookrunners on the Rule 144A / Regulation S offering